Health Equity News – June 16, 2025
- Standard race-free equations for assessing kidney function may underestimate risks for Black adults, according to a new analysis.The study, encompassing over 62,000 adults, revealed that while all eGFR...
- This reduction could lead to under-referral for Black patients.
- Kennedy Jr., HHS Secretary, recently dismissed all members of the CDC's Advisory Committee on Immunization Practices (ACIP).
Uncover critical insights into the latest challenges and advancements in health equity.A new analysis reveals that race-free kidney function equations might underestimate risks for Black adults,potentially leading to under-referral. The study underscores how accurate kidney disease assessment relies on biomarkers, advocating for a more equitable approach. Moreover,HHS secretary Robert F. Kennedy Jr. has replaced the CDC’s vaccine advisory panel, sparking debate, while socioeconomic disparities impact multiple myeloma patients’ quality of life. Unaddressed side effects negatively affect lymphoma care. News Directory 3 delivers concise coverage of these crucial developments. Explore these issues and discover what’s next in the ongoing pursuit of fairer healthcare practices.
Kidney Disease risk: Biomarkers Play Key Role in Equitable Assessment
Updated June 16, 2025
Standard race-free equations for assessing kidney function may underestimate risks for Black adults, according to a new analysis.The study, encompassing over 62,000 adults, revealed that while all eGFR equations linked lower kidney function to adverse outcomes, the creatinine-only equation reduced apparent racial differences.
This reduction could lead to under-referral for Black patients. equations incorporating both creatinine and cystatin C maintained disparities and provided more accurate risk predictions, suggesting a more equitable approach to kidney disease risk assessment. Researchers emphasize that removing race from algorithms without more precise biomarkers may unintentionally harm those already facing a disproportionate burden of chronic kidney disease. The study highlights the critical role biomarkers play in ensuring fair and accurate medical assessments.
In other health news, Robert F. Kennedy Jr., HHS Secretary, recently dismissed all members of the CDC’s Advisory Committee on Immunization Practices (ACIP). Kennedy cited the need to restore public trust in vaccine policy and alleged conflicts of interest. Critics, including Paul Offit, a former ACIP member, suggest this politicizes vaccine guidance and undermines public health confidence.
Francesco Sparano, MSc, discussed findings from the GIMEMA-CLARITY study at the 2025 European Hematology Association Congress. The study examined socioeconomic inequalities and their impact on the health-related quality of life (HRQoL) of patients with relapsed/refractory multiple myeloma. Patients with lower socioeconomic status consistently reported worse quality of life, more severe symptoms, and greater functional impairments, despite access to universal healthcare.
Lorna Warwick, CEO of the Lymphoma Coalition, also spoke at the EHA Congress about the burden of adverse effects on patients with lymphoma and chronic lymphocytic leukemia (CLL). Warwick presented findings from the 2024 Global Patient Survey, noting that unaddressed symptoms, like fatigue, can significantly impact patient confidence in their care plans, leading to worse health outcomes.
What’s next
Further research is needed to refine kidney disease risk assessment tools and address socioeconomic disparities in healthcare to improve patient outcomes and maintain public trust in medical institutions.